<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371059">
  <stage>Registered</stage>
  <submitdate>19/07/2016</submitdate>
  <approvaldate>22/07/2016</approvaldate>
  <actrnumber>ACTRN12616000966493</actrnumber>
  <trial_identification>
    <studytitle>Assessment of the use of spironolactone on the endothelial glycocalyx in patients with kidney transplants</studytitle>
    <scientifictitle>Assessment of the use of spironolactone on the endothelial glycocalyx in patients with kidney transplants</scientifictitle>
    <utrn />
    <trialacronym>ASGARD</trialacronym>
    <secondaryid>E35-2015</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney transplant</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Spironolactone 25mg, oral tablet, once daily for 2 months. Adherence to be monitored by questionnaire and return of empty drug packets. Wash-out period of 1 month. Then crossover to standard-of-care for 2 months (total trial period of 5 months).</interventions>
    <comparator>Compared to standard-of-care - i.e. regular nephrologist or general practitioner care and continuation of any current medications,  </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in glycocalyx parameters by:
1. Glycocheck value (sublingual camera measurement of the glycocalyx)
2. ELISA of syndecan-1 on serum samples
3. ELISA of hyaluronan on serum samples</outcome>
      <timepoint>5 months post initial randomisation of study arm</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in markers of endothelial dysfunction by:
1. ELISA of von Willebrand Factor on serum samples
2. ELISA of vascular cell adhesion molecule-1 (VCAM-1) on serum samples
3. Urinary microalbuminuria</outcome>
      <timepoint>5 months post initial randomisation of study arm</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Kidney transplant &gt;1 year ago</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Malignancy, pregnancy, inability to consent, known haematological disorders, serum potassium &gt; 5.0 mmol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Based on a previously published article (Nieuwdorp et al, J Appl Physiol 2008), the number required to detect a 0.2micrometre difference in the glycocalyx for a significance level of 5% and power of 80% in a paired design (i.e. measuring outcomes before and after an intervention) is n=10. We plan to recruit n=10 in each arm (total 20).</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>26/07/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Maroondah Hospital - Ringwood East</hospital>
    <hospital>Angliss Hospital - Upper Ferntree Gully</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3135 - Ringwood East</postcode>
    <postcode>3156 - Upper Ferntree Gully</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Renal Medicine, Box Hill Hospital</primarysponsorname>
    <primarysponsoraddress>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Eastern Clinical Research Unit, Monash University</fundingname>
      <fundingaddress>Level 2, 5 Arnold Street, Box Hill 3128, Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The glycocalyx is a particle that is important in maintaining blood vessel health. Patients with kidney disease have impaired blood vessel function, and previous studies have indicated that the glycocalyx is affected in those who have kidney disease. Laboratory studies indicate that the use of spironolactone, a common medication used for blood pressure, heart failure and to reduce protein in the urine, can have beneficial effects on the glycocalyx. The purpose of this study is to assess if the glycocalyx is affected in people who have kidney transplants, and whether spironolactone has any additional protective benefits on the glycocalyx.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Eastern Health HREC</ethicname>
      <ethicaddress>Level 2, 5 Arnold Street, Box Hill 3128, Victoria</ethicaddress>
      <ethicapprovaldate>7/07/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>19/05/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Hui Liew</name>
      <address>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</address>
      <phone>+61390918870</phone>
      <fax>+61398996810</fax>
      <email>hui.liew@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hui Liew</name>
      <address>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</address>
      <phone>+61390918870</phone>
      <fax>+61398996810</fax>
      <email>hui.liew@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hui Liew</name>
      <address>Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria</address>
      <phone>+61390918870</phone>
      <fax>+61398996810</fax>
      <email>hui.liew@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>